FDA OKs First-line Nivolumab + Ipilimumab in Advanced HCC

Approval for the combination therapy is based on improved survival and response rates from CHECKMATE-9DW.
Medscape Medical News

source https://www.medscape.com/viewarticle/fda-oks-first-line-nivolumab-ipilimumab-advanced-hcc-2025a10008rs?src=rss